Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a multicenter observational retrospective cohort study that aims to study the morphological characteristics of the lung parenchyma of SARS-CoV2 positive patients identifiable in patterns through artificial intelligence techniques and their impact on patient outcome.
Description: Describe the parenchymal lung damage induced by COVID-19 through a qualitative analysis with chest CT through artificial intelligence techniques.
Measure: A qualitative analysis of parenchymal lung damage induced by COVID-19 Time: Until patient discharge from the hospital (approximately 6 months)Description: Describe the parenchymal lung damage induced by COVID-19 through a quantitative analysis with chest CT through artificial intelligence techniques.
Measure: A quantitative analysis of parenchymal lung damage induced by COVID-19 Time: Until patient discharge from the hospital (approximately 6 months)Description: The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure assessed as intensive care mortality.
Measure: The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure. Time: Until patient discharge from the hospital (approximately 6 months)Description: The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure assessed as hospital mortality.
Measure: The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure. Time: Until patient discharge from the hospital (approximately 6 months)Description: The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure assessed as days free from mechanical ventilation.
Measure: The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure. Time: Until patient discharge from the hospital (approximately 6 months)Description: The hypothesis is that the uso of deep neural network models for lung segmentation in Acute Respiratory Distress Syndrome (ARDS) in animal models and Chronic Obstructive Pulmonary Disease (COPD) in patients that could be applied to self-segment the lungs of COVID-19 patients through a learning transfer mechanism with artificial intelligence.
Measure: Automated segmentation of lung scans of patients with COVID-19 and ARDS. Time: Until patient discharge from the hospital (approximately 6 months)Description: Expand the knowledge of chest CT features in COVID-19 patients and their detail through the use of machine learning and other quantitative techniques comparing CT patterns of COVID-19 patients to those of patients with ARDS.
Measure: Knowledge of chest CT features in COVID-19 patients and their detail through the use of machine learning and other quantitative techniques. Time: Until patient discharge from the hospital (approximately 6 months)Description: Determine the capacity within which the artificial intelligence analysis that uses deep learning models can be used to predict clinical outcomes from the analysis of the characteristics of the chest CT obtained within 7 days of hospital admission; combining quantitative CT data with clinical data.
Measure: The ability within which the analysis of artificial intelligence that uses deep learning models can be used to predict clinical outcomes Time: Until patient discharge from the hospital (approximately 6 months)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports